ERK1/2 signaling pathways involved in VEGF release in diabetic rat retina

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 10, 2010, Pages 5226-5233

  Ye, Xiaofeng ^a   Xu, Gezhi ^a   Chang, Qing ^a   Fan, Jiaweng ^a   Sun, Zhongcui ^a   Qin, Yaowu ^a   Jiang, Alice C ^b  

^a FUDAN UNIVERSITY   (China)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TRANSCRIPTION FACTOR AP 1; VASCULOTROPIN; 1,3 BUTADIENE DERIVATIVE; DNA; ENZYME INHIBITOR; MESSENGER RNA; NITRILE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DNA BINDING; DOWN REGULATION; ENZYME ACTIVATION; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; ENZYME IMMUNOASSAY; EXPERIMENTAL DIABETES MELLITUS; GEL MOBILITY SHIFT ASSAY; GENETICS; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT; VITREOUS BODY; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; BUTADIENES; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; DNA; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME INHIBITORS; IMMUNOENZYME TECHNIQUES; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NITRILES; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 77956231461     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-4899     Document Type: Article

References (38)

1. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy: II. prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol. 1984;102:520-526.
2. Barber AJ. A new view of diabetic retinopathy: a neurodegenerative disease of the eye. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:283-290.
3. Ambati J, Chalam KV, Chawla DK, et al. Elevated gamma aminobutyric acid, glutamate, and vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch Ophthalmol. 1997;115:1161-1166.
4. Sone H, Kawakami Y, Okuda Y, et al. Ocular vascular endothelial growth factor levels in diabetic rats are elevated before observable retinal proliferative changes. Diabetologia. 1997;40:726-730.
5. Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoformselective inhibitor. Diabetes. 1997;46:1473-1480.
6. Tilton RG, Kawamura T, Chang KC, et al. Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor. J Clin Invest. 1997;99:2192-2202.
7. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995;146:1029-1039.
8. Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, Adamis AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov. 2006;5:123-132.
9. Comer GM, Ciulla TA. Pharmacotherapy for diabetic retinopathy. Curr Opin Ophthalmol. 2004;15:508-518.
10. Hussain N, Ghanekar Y, Kaur I. The future implications and indications of anti-vascular endothelial growth factor therapy in ophthalmic practice. Indian J Ophthalmol. 2007;55:445-450.
11. Slevin M, Krupinski J, Slowik A, Rubio F, Szczudlik A, Gaffney J. Activation of MAP kinase (ERK-1/ERK-2), tyrosine kinase and VEGF in the human brain following acute ischaemic stroke. Neuroreport. 2000;11:2759-2764.
12. Tam BY, Wei K, Rudge JS, et al. VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med. 2006;12:793-800.
13. Berra E, Pages G, Pouysségur J. MAP kinases and hypoxia in the control of VEGF expression. Cancer Metastasis Rev. 2000;19:139-145.
14. Papachristou DJ, Papachristou GJ, Papaefthimiou OA, et al. The MAPK-AP-1/-Runx2 signalling axes are implicated in chondrosarcoma pathobiology either independently or via up-regulation of VEGF. Histopathology. 2005;47:565-574.
15. Janknecht R, Ernst WH, Pingoud V, Nordheim A. Activation of ternary complex factor Elk-1 by MAP kinases. EMBO J. 1993;12: 5097-5104.
16. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem. 1995;270:16483-16486.
17. Karin M, Liu Z, Zandai E. AP-1 function and regulation. Curr Opin Cell Biol. 1997;9:240-246.
18. Shima DT, Kuroki M, Deutsch U, Ng YS, Adamis AP, D'Amore PA. The mouse gene for vascular endothelial growth factor: genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences. J Biol Chem. 1996;271:3877-3883.
19. Tiscerr E, Mitchell R, Hartman T, et al. The human gene for vascular endothelial growth factor: multiple protein forms are encoded through alternative exon splicing. J Biol Chem. 1991;266: 11947-11954.
20. Hoshi S, Nomoto K, Kuromitsu J, Tomari S, Nagata M. High glucose induced VEGF expression via PKC and ERK in glomerular podocytes. Biochem Biophys Res Commun. 2002;290:177-184.
21. Cho ML, Cho CS, Min SY, et al. Cyclosporine inhibition of vascular endothelial growth factor production in rheumatoid synovial fibroblasts. Arthritis Rhem. 2002;46:1202-1209.
22. Lukiw WJ, Gordon WC, Rogaev EI, Thompson H, Bazan NG. Presenilin-2 (PS2) expression upregulation in a model of retinopathy of prematurity and pathoangiogenesis. Neuroreport. 2001;12: 53-57.
23. Xu S, Green M, Kingsley L, Webber S, Rowe D. A comparison of quantitative-competitive and realtime PCR assays using an identical target sequence to detect Epstein-Barr virus viral load in the peripheral blood. J Virol Methods. 2006;137:205-212.
24. Lampo E, Van Poucke M, Vandesompele J, Erkens T, Van Zeveren A, Peelman LJ. Positive correlation between relative mRNA expression of PRNP and SPRN in cerebral and cerebellar cortex of sheep. Mol Cell Probes. 2009;23:60-64.
25. Erkens T, Van Poucke M, Vandesompele J, Goossens K, Van Zeveren A, Peelman LJ. Development of a new set of reference genes for normalization of realtime RT-PCR data of porcine backfat and longissimus dorsi muscle, and evaluation with PPARGC1A. BMC Biotechnol. 2006;6:41.
26. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402-408.
27. Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase cascades. Adv Cancer Res. 1998;74:49-139.
28. Cavaletti G, Miloso M, Nicolini G, Scuteri A, Tredici G. Emerging role of mitogen-activated protein kinases in peripheral neuropathies. J Peripher Nerv Syst. 2007;12:175-194.
29. Peng M, Li Y, Luo Z, Liu C, Laties AM, Wen R. Alpha2-adrenergic agonists selectively activate extracellular signal-regulated kinases in Müller cells in vivo. Invest Ophthalmol Vis Sci. 1998;39:1721-1726.
30. Teruel MN, Meyer T. Translocation and reversible localization of signaling proteins: a dynamic future for signal transduction. Cell. 2000;103:181-184.
31. Downward J. The ins and outs of signaling. Nature. 2001;411: 759-762.
32. Giuliani N, Lunghi P, Morandi F, et al. Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis. Leukemia. 2004;18: 628-635.
33. Urata Y, Yamaguchi M, Higashiyama Y, et al. Reactive oxygen species accelerate production of vascular endothelial growth factor by advanced glycation end products in RAW264.7 mouse macrophages. Free Radic Biol Med. 2002;32:688-701.
34. Khan ZA, Chakrabarti S. Cellular signaling and potential new treatment targets in diabetic retinopathy (review). Exp Diabetes Res. 2007;2007:31867.
35. Cho HJ, Kang JH, Kwak JY, et al. Ascofuranone suppresses PMAmediated matrix metalloproteinase-9 gene activation through the Ras/Raf/MEK/ERK-and Ap1-dependent mechanisms. Carcinogenesis. 2007;28:1104-1110.
36. Xu L, Fukumura D, Jain RK. Acidic extracellular pH induces vascular endothelial growth factor (VEGF) in human glioblastoma cells via ERK1/2 MAPK signalling pathway. J Biol Chem. 2002;277: 11368-11374.
37. Feng H, Xiang H, Mao Y-M, et al. Human Bcl-2 activates ERK signaling pathway to regulate activating protein-1, lens epitheliumderived growth factor and downstream genes. Oncogene. 2004; 23:7310-7321.
38. Salnikow K, Kluz T, Costa M, et al. The regulation of hypoxic genes by calcium involves c-Jun/AP-1, which cooperates with hypoxiainducible factor 1 in response to hypoxia. Mol Cell Biol. 2002;22: 1734-1741.